Background
==========

*Plasmodium falciparum* malaria still kills \~0.7 million people each year. The majority of those who die are children in sub-Saharan Africa, but \~43,000 patients still die each year in the Asia-Pacific \[[@B1]\]. Admission clinical features that predict death have been defined in African children \[[@B2]-[@B6]\]. For Asian adults the relationships between mortality and a wide range of individual variables have been tested, including parasitaemia and parasite-stage distribution and intraleucocytic malaria pigment on blood smears, renal failure, hypoglycaemia, cerebral malaria, acidosis and older age \[[@B7]-[@B14]\] (Additional file [1](#S1){ref-type="supplementary-material"}, Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). However, there have been few assessments of which combinations of prognostic factors are the best predictors of mortality. Although a single definition may not be appropriate everywhere, it is important to attempt to define severe malaria to aid clinicians in recognizing those at risk of death and in need of parenteral therapy. This will inform decisions on whether transfer to a higher level of care, if available, is appropriate, facilitate comparison between datasets, longitudinal epidemiological surveillance, and robust case definitions in evaluation of interventions \[[@B11],[@B15]\].

###### 

Clinical variables included in the ten sets, used in the logistic regression analyses

  **Variable**                                             **Bed side**   **Bedside and simple lab**   **WHO 1990**   **WHO 2000**   **Adapted AQ**   **Adapted AQ plus late stages**   **BCAM**   **RCAM**   **MSA**   **MPI**
  -------------------------------------------------------- -------------- ---------------------------- -------------- -------------- ---------------- --------------------------------- ---------- ---------- --------- ---------
  Seizures before admission                                X              X                            X              X              \-               \-                                \-         \-         \-        \-
  Clinical anaemia                                         X              X                            \-             \-             \-               \-                                \-         \-         \-        \-
  Clinical jaundice                                        X              X                            X              X              \-               \-                                \-         \-         \-        \-
  Bleeding                                                 \-             \-                           X              X              \-               \-                                \-         \-         \-        \-
  Blackwater fever                                         \-             \-                           X              X              \-               \-                                \-         \-         \-        \-
  Temperature                                              X              X                            X              \-             \-               \-                                \-         \-         \-        \-
  Pulse                                                    X              X                            \-             \-             \-               \-                                \-         \-         \-        \-
  Respiratory rate                                         X              X                            \-             X              \-               \-                                \-         X          \-        \-
  Respiratory distress, requiring mechanical ventilation   \-             \-                           \-             \-             \-               \-                                \-         \-         X         \-
  Liver palpable                                           X              X                            \-             \-             \-               \-                                \-         \-         \-        \-
  GCS Total                                                X              X                            X              X              X                X                                 X          X          X         X
  Pulmonary oedema                                         \-             \-                           X              X              \-               \-                                \-         \-         \-        \-

X = included, - = not included.

BCAM score uses serum bicarbonate as a marker of acidosis with cut-off values of ≥24 mmol/L (score = 0) for normal, ≥15- \< 24 mmol/L (score = 1) for deranged, and \<15 mmol/L (score = 2) for very deranged along with thresholds for coma of GCS ≤14 and GCS ≤10 \[[@B23]\]. The acidosis and coma scores were summed to give the BCAM score, ranging from 0--4.

RCAM score uses respiratory rate as a surrogate marker for acidosis with cut offs of \<20 breaths/min (score = 0) for normal, 20--39 breaths/min (score = 1) for deranged, and ≥40 breaths/min (score = 2) for very deranged.

The MSA score was defined as sum of 1 (severe anaemia \[haemoglobin, \<5 g/dL\]) + 2 (acute renal failure \[serum creatinine, \>3 mg/dL or 250 μmol/L\]) + 3 (respiratory distress, requiring mechanical ventilation) + 4 (cerebral malaria \[GCS \<11\]), in which each variable was scored as 0 or 1, depending on its absence or presence, respectively \[[@B22]\].

###### 

Laboratory variables included in the ten sets, used in the logistic regression analyses

  **Blood test variable**      **Bed side**   **Bedside and simple lab**   **WHO 1990**   **WHO 2000**   **Adapted AQ**   **Adapted AQ plus late stages**   **BCAM**   **RCAM**   **MSA**   **MPI**
  --------------------------- -------------- ---------------------------- -------------- -------------- ---------------- --------------------------------- ---------- ---------- --------- ---------
  Admission parasitaemia            \-                    X                     X              X               X                         X                     \-         \-        \-         X
  Pigmented stages                  \-                    X                     \-             \-              \-                        X                     \-         \-        \-         X
  Modal Stage                       \-                    X                     \-             \-              \-                       \-                     \-         \-        \-        \-
  Haematocrit                       \-                    X                     X              X               X                         X                     \-         \-        \-        \-
  Haemoglobin                       \-                    \-                    \-             \-              \-                       \-                     \-         \-         X        \-
  White cell count                  \-                    \-                    \-             \-              \-                       \-                     \-         \-        \-        \-
  Potassium ^S^                     \-                    \-                    \-             \-              \-                       \-                     \-         \-        \-        \-
  Creatinine ^S^                    \-                    \-                    X              X               X                         X                     \-         \-         X        \-
  Urea ^S^                          \-                    \-                    \-             \-              \-                       \-                     \-         \-        \-        \-
  Urea:creatinine ratio ^S^         \-                    \-                    \-             \-              \-                       \-                     \-         \-        \-        \-
  Total bilirubin^S^                \-                    \-                    X              \-              X                         X                     \-         \-        \-         X
  Direct bilirubin ^S^              \-                    \-                    \-             \-              \-                       \-                     \-         \-        \-        \-
  Alkaline phosphatase ^S^          \-                    \-                    \-             \-              \-                       \-                     \-         \-        \-        \-
  AST ^S^                           \-                    \-                    \-             \-              \-                       \-                     \-         \-        \-        \-
  ALT ^S^                           \-                    \-                    \-             \-              \-                       \-                     \-         \-        \-        \-
  Albumin ^S^                       \-                    \-                    \-             \-              \-                       \-                     \-         \-        \-        \-
  Bicarbonate ^S^                   \-                    \-                    X              X               X                         X                     X          \-        \-        \-
  Glucose ^P^                       \-                    \-                    X              X               X                         X                     \-         \-        \-        \-
  Lactate ^P^                       \-                    \-                    \-             X               X                         X                     \-         \-        \-         X

X = included, - = not included. ^S^ = serum, ^P^ = plasma.

Several definitions, classifications and severity scores have been proposed. The World Health Organization (WHO) has produced three guidelines which include definitions of severe malaria (Additional file [1](#S1){ref-type="supplementary-material"}, Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}) \[[@B16]-[@B18]\]. A slightly stricter definition of severe malaria ('AQ') was developed for a clinical trial in Vietnam \[[@B19]\] and adapted (with the addition of plasma lactate and serum bicarbonate measurements) for a trial in Thailand \[[@B20]\] and the subsequent multicentre SEAQUAMAT trial which enrolled 1461 Asian patients \[[@B21]\]. The malaria severity assessment score (MSA), based on haemoglobin, serum creatinine, requirement for mechanical ventilation and Glasgow coma score (GCS) was developed in central India \[[@B22]\].

Recently, in order to simplify and, therefore, broaden usage, the coma acidosis malaria (CAM) score was developed \[[@B23]\], based on data from Asian adults with severe malaria \[[@B21]\]. A score of \<2/5, when tested with data from different studies in Vietnamese and Bangladeshi adults, had a positive predictive value (PPV) for survival of 94-95%, suggesting that these patients could be cared for without admission to an intensive care unit (ICU).

The clinical and laboratory features of adults with falciparum malaria recruited prospectively to hospital-based studies on the western border of Thailand between 1986--2002, conducted by the Mahidol University-Oxford Tropical Medicine Research Unit and colleagues, were analysed. The specificity and sensitivity of the different severe malaria definitions and scoring systems were examined and simple models to identify adults at risk of death built.

Methods
=======

Study sites, years and studies
------------------------------

Data from 988 adult (≥15 years) patients with asexual forms of *P. falciparum* present on peripheral blood slides, admitted to hospital with malaria and then recruited to clinical research studies on the western border of Thailand between 1986 and 2002 were analysed. Patients were recruited at hospitals in Kanchanaburi (1986--1993; n = 571), Sangklaburi (1994--1995; n = 74), and Mae Sot (1995--2002; n = 343) and described in a series of papers \[[@B24]\]. All patients gave informed consent to participation and all studies were approved by the Ethics Committee of the Faculty of Tropical Medicine, Mahidol University and/or the Ethical and Scientific Review Subcommittee of the Ministry of Public Health, Government of Thailand.

Clinical and laboratory assessment
----------------------------------

As patients were recruited to a variety of studies, clinical and laboratory evaluations varied. All patients had a full history and examination performed and haematocrit and parasitaemia determined. Thick and thin blood films were stained immediately with Field's stain and parasites counted and staged \[[@B7],[@B8]\]. Admission blood samples for full blood count, serum sodium, potassium, creatinine, urea, total bilirubin, direct bilirubin, alkaline phosphatase, alanine transaminase (ALT), aspartate transaminase (AST), plasma lactate, glucose and, except in 1994, for plasma bicarbonate. Lumbar punctures were performed for the majority of patients with reduced GCS and cerebrospinal fluid cell, protein and glucose concentrations determined and Gram stains examined.

Management
----------

The anti-malarial treatment regimens used in clinical studies in western Thailand changed over the 18 years as new anti-malarials were introduced and were:

1\. Non-artemisinin-based parenteral treatment:

Intravenous quinine dihydrochloride with or without a 20 mg salt/kg or 7 mg/kg loading dose followed by 10 mg/kg every 8 h followed by oral quinine salt 10 mg/kg every 8 h, combined, when the patient was able to take oral medication, with oral quinine alone or with oral tetracycline, doxycycline, mefloquine (alone or combined with sulphadoxine-pyrimethamine (SP)) or single dose primaquine to give a total treatment course of 7 days.

2\. Non-artemisinin-based oral treatment:

Oral quinine sulphate 10 mg salt/kg every 8 h alone or with oral tetracycline, doxycycline, mefloquine (alone or combined with SP), single dose primaquine or proguanil to give a total treatment course of 7 days.

Or oral mefloquine (alone or combined with SP) at 15 mg base/kg on the first day with or without 10 mg/kg on the next day

Or oral halofantrine (8 mg/kg at 0, 6, 12 h) with tetracycline plus or minus oral quinine

3\. Artemisinin-based parenteral treatment:

Intravenous artesunate (Guilin Pharmaceutical Factory No. 2, Guangxi, People's Republic of China); 2.4 mg/kg stat, 1.2 mg/kg at 12 h followed by 1.2 mg/kg every 24 h) or intramuscular artemether (3.2 mg/kg stat followed by 1.6 mg/kg every 24 h) for 7 days alone or with oral doxycycline, tetracycline or mefloquine (alone or combined with SP) with or without primaquine. Sixty-nine patients were treated with iv artesunate combined with iv quinine followed by the above oral regime \[[@B25]\].

4\. Artemisinin-based oral treatment:

Oral artesunate or artemether (4 mg/kg for 3 days or 2 mg/kg for 7 days) alone or with oral doxycycline, tetracycline or mefloquine (alone or combined with SP) with or without primaquine. Eighteen patients received oral dihydroartemisinin (4 mg/kg) in replacement for one artesunate daily dose \[[@B26]\].

Supportive treatment was in accordance with guidelines \[[@B17],[@B27]\]. Facilities for urinary catheter and nasogastric tube placement, blood transfusion and lumbar puncture were available at Sangklaburi Hospital. In addition, mechanical ventilation, peritoneal dialysis and central venous access were available at Kanchanaburi and Mae Sot.

Statistical analysis and modelling
----------------------------------

Six main models have been used to define severe malaria in adults, those published by WHO and the AQ, MSA and CAM scores \[[@B16]-[@B23]\] (Additional file [1](#S1){ref-type="supplementary-material"}). The accuracy of the APACHE II score \[[@B28]\] could not be assessed as not all necessary laboratory variables were measured, and the definition of WHO 1986 was not evaluated \[[@B16]\]. Data were not collected specifically for this analysis and in order to examine the sensitivity and specificity of WHO 1990 and 2000 definitions \[[@B17],[@B18]\], minor adaptations were made to allow assessment (Additional file [1](#S1){ref-type="supplementary-material"}, Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). Where the WHO 2000 definition \[[@B18]\] does not include quantitative cut offs, the WHO 1990 \[[@B17]\] cut offs have been used. As blood pH, and hence base deficit, data were not available, calculation of the CAM score was not possible and so the modified CAM scores, BCAM and RCAM were evaluated, using serum bicarbonate and respiratory rate, respectively, as surrogates of acidosis (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}).

Statistical analyses were performed using Stata (v11.0; Stata Corporation, USA). All univariate comparisons between survivors and patients who died were performed using logistic regression and adjusted for study site. Ten sets of clinical and laboratory assay variables (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}) were used to construct diagnostic rules to predict death. Logistic regression analysis with a stepwise forward variable selection procedure was employed to find independent predictors of death at P \< 0.055, and P ≥ 0.055 for entry and removal, respectively. Fractional polynomials \[[@B29]\] were used to test for non-linear relationships between outcome variable and continuous covariates. All models were adjusted for artemisinin-based combination therapy (ACT) and study site. The identified model was rerun on the maximum available sample size and each of the variables not in the model were tested for inclusion using the Wald test. The predictive utility of each final model was assessed by receiver operating characteristic (ROC) curve analysis.

Malaria prognostic index
------------------------

Variables selected into any final logistic regression model, based on published criteria (see above), were used to define the malaria prognostic index (MPI). Since for all logistic models (above), inclusion of study site as an independent variable did not improve the model nor change the co-efficients for other covariates significantly, it was not included in the development of the MPI. Each variable was categorized into four groups using rounded quartiles or commonly used cut offs (as for GCS). Univariate logistic models (with sets of corresponding binary variables) were fitted and categories with similar (P \> 0.05) odds ratios (OR) were grouped together. Co-efficients of the final multivariate model were rounded to the nearest integer and used to calculate for each patient a linear combination of variables (i. e, sum of variables multiplied by the rounded co-efficients) -- the MPI. The MPI was calculated for each patient and the ROC analysis used to evaluate its prognostic utility.

The predictive value of the MPI was further evaluated using cross validation \[[@B30]\] on a subset of data with no missing values for variables chosen to define MPI. Each observation in this subset was sequentially removed, logistic regression with stepwise variable selection was performed on the remaining n-1 observations using all categorized variables, and the final model was used to calculate sensitivity, specificity on n-1 observations and classification results for the one excluded observation. Co-efficients were rounded to integers and cut offs for the linear predictor between two and six were used. For each cut off, classification results for observations excluded from the subsequent models were used to calculate jacknife estimates of sensitivity and specificity.

Results
=======

Clinical presentation and outcome
---------------------------------

Of 988 hospitalized patients enrolled (Tables [3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}, [5](#T5){ref-type="table"}, [6](#T6){ref-type="table"}, [7](#T7){ref-type="table"} and [8](#T8){ref-type="table"}), two thirds were men and ages ranged from 15 to 74 years. The percentages with severe malaria, as defined by the WHO 1990, WHO 2000, adapted AQ, BCAM, RCAM and MSA scores \[[@B17],[@B18],[@B20]-[@B22]\], were widely spread at 61.2, 78.1, 41.7, 24.8, 22.7 and 5.6%, respectively (see Additional files [2](#S2){ref-type="supplementary-material"}, [3](#S3){ref-type="supplementary-material"}, and [4](#S4){ref-type="supplementary-material"}). The overall mortality was 7.8% (77/988). Using the WHO 1990, 2000 and adapted AQ definitions of severe malaria \[[@B17]-[@B20]\], the mortalities were 12.4%, 10% and 18.7%, in these groups, respectively.

###### 

Admission clinical history details for the three study sites

  **Variable**          **All patients**   **Kanchanaburi**   **Sangklaburi**   **Mae Sot**                                    
  --------------------- ------------------ ------------------ ----------------- ------------------ ---- ---------------- ----- ------------------
  No. male              982                654 (67)           569               371 (65)           74   42 (57)          339   241 (71)
  Age/years             979                27 (15--74)        564               26 (15--72)        73   25 (15--57)      342   28 (15--74)
  Body weight/kg        929                51 (26--165)       544               51 (32--80)        70   50 (26--89)      315   51 (32--165)
  Height/cm             441                160 (96--180)      199               160 (96--78)       2    154 (145--163)   240   160 (143--180)
  BMI kg/m^a^           440                33.5 (32.8-34.2)   198               33.0 (32.3-33.8)   2    42.1             240   33.8 (32.7-34.8)
  Prior malaria         780                445/335 (57)       464               256/208 (55)       52   26/26 (100)      264   163/101 (62)
  Prior malarial drug   988                268/720 (27)       571               233/338 (41)       74   6/68 (8)         343   29/314 (9)
  No. days ill          956                4 (1--31)          557               4 (1--31)          68   3 (1--30)        331   3 (1--21)
  Females pregnant      328                76/252 (23)        198               70/128 (35)        32   5/27 (16)        98    1/97 (1)
  Headache              921                843/78 (92)        520               484/36 (93)        72   66/6 (92)        329   293/36 (89)
  Rigors                875                454/421 (52)       491               309/182 (63)       60   15/45 (25)       324   130/194 (40)
  Vomiting              906                5 17/389 (57)      511               296/215 (58)       69   37/32 (54)       326   184/142 (56)
  Diarrhoea             850                160/690 (19)       461               90/371 (24)        65   8/57 (12)        324   62/262 (19)
  Abdominal pain        867                223/644 (26)       478               129/349 (27)       65   7/58 (11)        324   87/237 (27)
  Cough                 851                143/708 (17)       470               99/371 (21)        55   6/49 (11)        326   38/288 (12)
  Seizures              836                28/808 (3)         456               9/447 (2)          60   1/59 (2)         320   18/302 (6)

Number with/without symptom or sign or median (range) except ^a^ mean (95% CI) and ^b^ geometric mean (95% CI). Percentages shown in brackets. Location of hospitals included: Kanchanaburi (14.06 ^0^ N, 99.50 ^0^E), Sangklaburi 15.16 ^0^ N 98.56 ^0^E), Mae Sot (16.71 ^0^ N 98.57 ^0^E).

###### 

Admission clinical examination details for the three study sites

  **Variable**                  **All patients**   **Kanchanaburi**       **Sangklaburi**   **Mae Sot**                                            
  ----------------------------- ------------------ ---------------------- ----------------- --------------------- ---- --------------------- ----- ---------------------
  Dehydration                   781                428/353 (55)           424               182/242 (43)          41   13/28 (32)            316   233/83 (74)
  Anaemia                       932                274/658 (29)           529               161/368 (30)          68   10/58 (15)            335   103/232 (31)
  Jaundice                      969                226/743 (23)           561               137/424 (24)          72   9/63 (13)             336   80/256 (24)
  Temperature °C ^a^            963                38.5 (38.4-38.6)       552               38.4 (38.3-38.5)      74   38.5 (38.3-38.8)      337   38.7 (38.5-38.8)
  Pulse/min ^a^                 927                101.0 (99.9-102.2)     519               97.4 (95.9-98.9)      73   103.1 (99.2-106.9)    335   106.2 (104.6-108.0)
  BP systolic mmHg ^a^          924                108.3 (107.3- 109.3)   515               107.5 (106.2-108.9)   71   105.7 (102.2-109.3)   338   110.1 (108.3-111.8)
  BP diastolic mmHg ^a^         918                65.5 (64.7-66.3)       513               64.3 (63.3-65.4)      71   68.8 (66.6-71.0)      334   66.7 (65.3-68.0)
  Respiratory rate/min ^b^      909                24.3 (23.8-24.7)       508               22.8 (22.2-23.3)      70   28.1 (26.6-29.8)      331   25.9 (25.2-26.6)
  Abdominal tenderness          801                124/677 (15)           413               61/352 (15)           73   8/65 (11)             315   55/260 (17)
  Liver palpable                870                338/532 (39)           500               183/317 (37)          68   7/61 (10)             302   148/154 (49)
  Spleen palpable               885                190/695 (22)           506               94/412 (19)           71   0/71 (0)              308   96/212 (31)
  Cranial nerve abnormalities   515                35/480 (7)             230               23/207 (10)           15   2/13 (13)             270   10/260 (4)
  GCS Total                     944                15 (3--15)             529               15 (3--15)            73   15 (3--15)            342   15 (3--15)
  GCS Eyes                      941                4 (1--4)               526               4 (1--4)              73   4 (1--4)              342   4 (1--4)
  GCS Verbal                    939                5 (1--5)               526               5 (1--5)              73   5 (1--5)              342   5 (1--5)
  GCS Motor                     941                6 (1--6)               526               6 (1--6)              73   6 (1--6)              342   6 (1--6)
  Fundal haemorrhages           443                11/432 (3)             202               6/196 (3)             10   1/9 (10)              231   4/227 (2)

Number with/without or median (range) except ^a^ mean (95% CI) and ^b^ geometric mean (95% CI).

###### 

Admission haematology laboratory details for the three study sites

  **Variable**                  **All patients**   **Kanchanaburi**         **Sangklaburi**   **Mae Sot**                                                  
  ----------------------------- ------------------ ------------------------ ----------------- ------------------------ ---- ------------------------ ----- --------------------------
  Parasitaemia /μL^b,c^         953                72,694 (64.402-82,054)   540               53,766 (45,785-63,138)   74   71,793 (51,736-99,625)   339   117,827 (95,989-144,633)
  Rings %                       874                97 (1--100)              486               97 (6--100)              66   98 (42--100)             322   95 (1--100)
  Trophozoites %                874                3 (0--99)                486               2.5 (0--94)              66   2.0 (0--58)              323   4.0 (0--99)
  Schizonts %                   876                0 (0--25)                486               0 (0--12)                67   0 (0--6)                 320   0 (0--25)
  Pigmented stages \> 10^4^/L   868                274/594 (32)             482               121/361 (25)             66   13/53 (20)               322   140/180 (43)
  Trophozoites and schizonts%   874                4 (0--99)                486               3 (0--94)                66   2 (0--58)                321   5 (0--99)
  Modal Stage %                 833                55 (19--99)              446               56 (19--99)              66   70 (30--96)              339   53 (23--97)
  Haematocrit %                 962                37 (6--56)               549               37 (8--56)               74   38 (22--50)              285   38 (6--54)
  Haemoglobin g/dL ^a^          761                11.3 (11.1-11.5)         476               10.9 (10.7-11.1)         0    \-                       314   12.0 (11.6-12.3)
  White cells x 10^9^/L         889                6.8 (1.5-67.0)           519               6.6 (1.8-67)             56   5.7 (1.5-25)             292   7.1 (1.9-54)
  Neutrophils %                 863                75 (12--97)              507               73 (31--97)              64   74 (12--96)              281   77 (41-96)
  Platelets x10^9^/L            527                74 (0.5-404)             246               105 (16--384)            0    \-                       329   45 (1--404)

^c^ number of asexual parasites/1000 erythrocytes on thin film x haematocrit% × 125.6 or number of asexual parasites/200 white cells on thick film assuming white cell count 8 × 10^9^/L.

###### 

Admission biochemistry laboratory variables for the three study sites

  **Variable**                             **All patients**   **Kanchanaburi**      **Sangklaburi**   **Mae Sot**                                            
  ---------------------------------------- ------------------ --------------------- ----------------- --------------------- ---- --------------------- ----- ---------------------
  Sodium mmol/L^,\ d\ S^                   764                135.4 (93.8-155.0)    419               137.8 (94--155)       16   136.5 (130--141)      328   133 (111--146)
  Potassium mmol/L^,\ e\ S^                761                3.81 (1.2-7.51)       417               3.8 (1.2-7.5)         16   3.70 (3.3-4.3)        331   3.9 (1.8-7.1)
  Creatinine μmol/L ^f\ S^                 880                105.6 (35.2-1056)     475               114 (35--1056)        74   97 (66--202)          334   106 (39--836)
  Urea mmol/L ^g\ S^                       892                19.5 (3.5-226.5)      484               6.5 (1.5-56)          74   6.7 (2.5-18.7)        334   7.7 (1.3-81)
  Urea mmol/L:creatinine μmol/L ratio      879                0.070 (0.005-0.256)   474               0.060 (0.005-0.244)   74   0.067 (0.022-0.014)   331   0.078 (0.021-0.026)
  Total bilirubin μmol/L ^b,h,\ S^         859                28.9 (26.8 - 31.0)    456               23.6 (21.1-26.4)      73   29.4 (24.5-35.2)      330   38.0 (34.6-41.8)
  Direct bilirubin μmol/L ^I,\ S^          847                8.5 (0.3-488.6)       451               8.5 (0.3-487)         72   6.1 (1.5-152)         324   9.9 (1.0-389)
  Alkaline phosphatase IU/L ^b,j,\ S^      844                43.2 (41.1-45.3)      442               31.5 (29.8-33.3)      73   34.9 (31.9-38.2)      329   69.2 (64.2-74.6)
  AST IU/L ^k,\ S^                         858                41 (0.4-1795)         455               33 (5--210)           73   43 (0.4-183)          330   52 (10--1795)
  ALT IU/L ^b,l,\ S^                       856                20.7 (19. 5--22.0)    456               19.2 (17.6-21.1)      73   24.5 (21.3-28.2)      327   22.2 (20.4-24.1)
  Albumin g/L ^a,m,\ S^                    862                33.7 (33.2-34.2)      459               31.9 (31.2-32.7)      73   38.6 (37.0-40.1)      330   35.0 (34.3-35.7)
  Calcium (uncorrected) mmol/L ^a,n,\ S^   397                2.06 (1.47-2.56)      0                 \-                    73   2.12 (2.09-2.15)      324   2.05 (2.04-2.07)
  Phosphate mmol/L^b,o,S^                  291                0.82 (0.32-2.65)      0                 \-                    73   1.19 (0.32-1.87)      218   0.81 (0.32-2.65)
  Bicarbonate mmol/L ^a,p,\ S^             687                20.5 (20.2-20.8)      348               21.0 (20.5-21.4)      16   20.4 (18.9-22.0)      323   20.0 (19.4-20.5)
  Chloride mmol/L ^a,q,\ S^                752                102.2 (101.7-102.7)   407               103.7 (103.0-104.3)   16   103.3 (101.2-105.3)   329   100.2 (99.6-100.8)
  Glucose mmol/L ^r,\ P^                   846                6.4 (0.7-37. 5)       447               6.2 (1.5-38)          70   6.2 (3.5-25)          329   7.3 (0.7-31.1)
  Lactate mmol/L ^s,\ P^                   805                2.7 (0.3-27.6)        414               2.7 (0.4-28)          74   2.2 (0.9-16)          317   2.8 (0.3-22)

Number with/without or median (range) except ^a^ mean (95% CI) and ^b^ geometric mean (95% CI).

^d^ normal range 135--145 mmol/L; ^e^ normal range 3.5-5.5 mmol/L; ^f^ normal range 70--150 μmol/L; ^g^ normal range 2.5-6.7 mmol/L; ^h^ normal range 5.1-17 μmol/L; ^I^ normal range 1.7-5.1 mmol/L; ^j^ normal range 30--300 IU/L; ^k^ normal range 5--35 IU/L; ^l^ normal range 5--35 IU/L; ^m^ normal range 35--50 g/L; ^n^ normal range 2.2-2.6 mmol/L; ^o^ normal range 1.0-1.4 mmol/L; ^p^ normal range 21--28 mmol/L; ^q^ normal range 95--105 mmol/L; ^r^ normal range 3.5-5.5 mmol/L; ^s^ normal \<4 mmol/L.

###### 

Admission clinical variables for those who died and survived

  **Variable**                  **All patients**   **Survived**          **Died**   **P**                                                                
  ----------------------------- ------------------ --------------------- ---------- ------- --------------------- ---- ---- ----------------------- ---- ---------
  No. male                      982                654                   67         906     598                   66   76   56                      74   0.197
  Age/years                     979                27 (15--74)           \-         905     27 (15--74)           \-   74   26 (15--67)             \-   0.410
  Body weight/kg                929                51 (26--165)          \-         861     51 (26--165)          \-   68   50 (40--75)             \-   0.715
  Prior malaria                 780                445/335               57         748     438/310               59   32   7/25                    22   \<0.001
  Prior malarial drug           988                268/720               27         911     242/669               27   77   26/51                   34   0.310
  No. days ill                  956                4 (1--31)             \-         886     3 (1--31)             \-   70   4 (1--20)               \-   0.836
  No. females pregnant          328                76/252                23         308     75/233                24   20   1/19                    5    0.049
  Headache                      921                843/78                92         866     794/72                94   55   49/6                    89   0.511
  Rigors                        875                454/421               52         821     428/393               52   54   26/28                   48   0.522
  Vomiting                      906                517/389               57         855     484/371               56   51   33/18                   65   0.268
  Diarrheoa                     850                160/690               19         805     152/653               19   45   8/37                    18   0.805
  Abdominal pain                867                223/644               26         823     215/608               26   44   8/36                    18   0.200
  Cough                         851                143/708               17         806     136/670               17   45   7/38                    16   0.897
  Seizures                      836                28/808                3          786     18/768                2    50   10/40                   20   \<0.001
  Dehydration                   781                428/353               55         734     395/339               54   47   33/14                   70   0.063
  Anaemia                       932                274/658               29         862     236/626               27   70   38/32                   54   \<0.001
  Jaundice                      969                226/743               23         892     175/717               20   77   51/26                   66   \<0.001
  Temperature ^o^ C ^a^         963                38.5 (38.4 - 38.6)    \-         892     38.6 (38.5-38.6)      \-   71   38.0 (37.7-38.3)        \-   \<0.001
  Pulse/min ^a^                 927                101.0 (99.9-102.2)    \-         856     100.1 (99.0-101.2)    \-   71   113.3 (108.6--117.9)    \-   \<0.001
  BP systolic mmHg ^a^          924                108.3 (107.3-109.3)   \-         851     107.9 (106.9-108.9)   \-   73   113.5 (108.4-- 118.5)   \-   0.004
  BP diastolic mmHg ^a^         918                65.5 (64.7-66.3)      \-         846     65.4 (64.6-66.2)      \-   72   66.8 (63.6-70.0)        \-   0.247
  Respiratory rate/min ^b^      909                24.3 (23.8-24.7)      \-         837     23.9 (23.5-24.3)      \-   71   29.2 (26.9 - 31.6)      \-   \<0.001
  Abdominal tenderness          801                124/677               15         743     116/627               16   58   8/50                    14   0.689
  Liver palpable                870                338/532               39         800     299/501               38   70   39/31                   56   0.005
  Spleen palpable               885                190/695               22         818     172/646               21   67   18/49                   27   0.308
  Cranial nerve abnormalities   515                35/480                7          467     20/447                4    48   15/33                   31   \<0.001
  GCS Total                     944                15 (3--15)            \-         882     15 (3--15)            \-   62   9 (3--15)               \-   \<0.001
  GCS Eyes                      941                4 (1--4)              \-         881     4 (1--4)              \-   60   4 (1--4)                \-   \<0.001
  GCS Verbal                    939                5 (1--5)              \-         881     5 (1--5)              \-   58   1 (1--5)                \-   \<0.001
  GCS Motor                     941                6 (1--6)              \-         881     6 (1--6)              \-   60   5 (1--6)                \-   \<0.001
  Fundal haemorrhages           443                11/432                3          389     4/385                 1    54   7/47                    13   \<0.001

Number with/without or median (range) except ^a^ mean (95% CI) and ^b^ geometric mean (95% CI). Footnotes as for Table [3](#T3){ref-type="table"}.

###### 

Admission laboratory variables for those who died and survived

  **Variable**                          **All patients**   **Survived**              **Died**   **P**                                                    
  ------------------------------------- ------------------ ------------------------- ---------- ------------------------ ---- -------------------------- ---------
  Admission parasitaemia μL^b,c^        953                72,694 (64,402--82,054)   883        68,850 (60,837-77,917)   70   144,012 (86,460-239,876)   0.002
  Rings%                                874                97 (1--100)               811        98 (1--100)              63   48 (1--100)                \<0.001
  Trophozoites%                         874                3 (0--99)                 811        2 (0--99)                63   52 (0--99)                 \<0.001
  Schizonts%                            876                0 (0--25)                 813        0 (0--6)                 63   0 (0--25)                  \<0.001
  Pigmented stages \> 10^4^/L           868                274/594 (32%)             805        227/578 (28%)            63   47/16 (75%)                \<0.001
  Trophozoites and schizonts %          874                4 (0--99)                 811        2 (0--99)                63   52 (0--99)                 \<0.001
  Modal Stage %                         833                55 (19--99)               779        56 (23--99)              54   47 (19--94)                0.001
  Haematocrit %                         962                37 (6--56)                888        37 (6--56)               74   33 (12--50)                \<0.001
  Haemoglobin g/dL ^a^                  761                11.3 (11.1- 11.5)         704        11.4 (11.2- 11.6)        57   10.1 (9.5 -10.8)           \<0.001
  White cells x 10^9^/L                 889                6.8 (1.5-67.0)            818        6.6 (1.5 - 67)           71   11.2 (2.4 - 63)            \<0.001
  Neutrophils%                          863                75 (12--97)               796        75 (12--97)              67   72 (36--95)                0.101
  Platelets 10^9^/L                     527                74 (0.5-404)              491        75 (0.5 - 404)           36   50 (4--188)                0.001
  Sodium mmol/L^,\ d,\ S^               764                135.4 (93.8-155.0)        698        135.3 (100.4-155.0)      66   136.7 (93.8--153.0)        0.618
  Potassium mmol/L^,\ e,\ S^            761                3.81 (1.2-7.51)           696        3.80 (2.0 --7.51)        65   4.50 (1.2-7.1)             \<0.001
  Creatinine μmol/L ^f,\ S^             880                105.6 (35.2 - 1056)       810        105.6 (35.2 - 1056)      70   240 (46.6 - 880)           \<0.001
  Urea mmol/L ^g,\ S^                   892                19.5 (3.5-226.5)          821        18.7 (3.5-138)           71   58.2 (10.7 - 227)          \<0.001
  Urea mmol/L:creatinine μmol/L ratio   879                0.070 (0.005-0.256)       809        0.065 (0.005-0.257)      70   0.078 (0.030-0.260)        \<0.001
  Total bilirubin μmol/L ^b,h^          859                28.9 (26.8 - 31.0)        797        26.4 (24.6-28.4)         62   90.6 (69.6-118.1)          \<0.001
  Direct bilirubin μmol/L ^i^           847                8.5 (0.3-488.6)           787        8.3 (0.3 - 489)          60   40.3 (1.4 - 389)           \<0.001
  Alkaline phosphatase IU/L ^b,j^       844                43.2 (41.1-45.3)          781        42.1 (40.0-44.2)         63   60.7 (50.5-72.8)           \<0.001
  AST IU/L ^k^                          858                41.0 (0.4-1795)           796        40 (0.4 - 1795)          62   95 (22--1200)              0.001
  ALT IU/L ^b,l^                        856                20.7 (19. 5--22.0)        794        19.7 (18.5-20.9)         62   41.3 (33.6-50.8)           \<0.001
  Albumin g/L ^a,m^                     862                33.7 (33.2-34.2)          798        33.9 (33.4-34.4)         64   30.6 (28.5-32.7)           0.001
  Calcium (uncorrected) mmol/L ^a,n^    397                2.06 (1.47-2.56)          369        2.06 (1.52-2.56)         28   2.06 (1.47-2.40)           0.385
  Phosphate mmol/L ^b,o^                291                0.82 (0.32-2.65)          272        0.81 (0.32-2.10)         19   1.23 (0.48-2.65)           \<0.001
  Serum bicarbonate mmol/L ^a,p^        687                20.5 (20.2-20.8)          629        21.0 (20.7-21.3)         58   14.7 (13.1-16.3)           \<0.001
  Serum chloride mmol/L ^a,q^           752                102.2 (101.7-102.7)       688        102.3 (101.9-102.7)      64   100.6 (98.0-103.2)         0.023
  Plasma glucose mmol/L ^r^             846                6.4 (0.7-37. 5)           778        6.4 (0.7 - 38)           68   6.8 (2.2-18.5)             0.139
  Plasma lactate mmol/L ^s^             805                2.7 (0.3-27.6)            741        2.5 (0.3 - 22)           64   8.5 (1.9 - 28)             \<0.001

Number with/without or median (range) except ^a^ mean (95% CI) and ^b^ geometric mean (95% CI). Footnotes as for Tables [3](#T3){ref-type="table"}, [5](#T5){ref-type="table"} and [6](#T6){ref-type="table"}.

Mortality did not significantly differ between the three sites (9% in Kanchanaburi, 3% in Sangklaburi and 8% in Mae Sot; P = 0.20). Artemisinin derivatives were given to 7% of patients in Kanchanaburi, 77% in Sangklaburi and 83% in Mae Sot (P \< 0.001), reflecting temporal changes in treatment policy and study protocols. Patients in Kanchanaburi had received prior malarial treatment more frequently than at other sites and women there were more often pregnant. Patients in Mae Sot presented with lower coma scores (69% with coma score of 15 compared to \>80% at the other sites and 20% with coma score ≤11 compared to 9-10% in the other sites), higher parasitaemia, higher proportions of trophozoites on admission film and a greater likelihood of a palpable liver or spleen (Tables [3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}, [5](#T5){ref-type="table"}, and [6](#T6){ref-type="table"}). However, other key variables such as haematocrit, bicarbonate and lactate were similar across all sites.

Forty-one admission variables were significantly associated (P \< 0.05) with death on bivariate analysis (Tables [7](#T7){ref-type="table"} and [8](#T8){ref-type="table"}). Variables previously associated with mortality that were not significantly associated with death in our cohort were patient age, the number of days of illness before admission, and plasma glucose. Although there was no apparent overall relationship between mortality and age, mortality was higher with increasing age for those treated with quinine (OR (95% CI) 1.029 (1.006-1.051) P = 0.012), but not for those treated with artemisinins (OR 0.953 (0.904-1.005) P = 0.078).

Prognostic value of parasite staging
------------------------------------

Staging of parasite development on peripheral blood smears provides prognostic information additional to the parasite count itself; the median percentage of ring stages amongst those who survived was 98% and amongst those who died 48% (P = 0.0001). The percentage of the modal parasite stage was significantly lower amongst those who died than in those who survived (P = 0.0002), suggesting that lower circulating parasite stage synchronicity was associated with death. Using the cut offs of Silamut and White of pigmented stages \>10^4^/μL or a parasitaemia of \>5 x 10^5^/μL \[[@B7]\], the sensitivity and specificity for predicting death were 84% and 67%, respectively.

Therapeutic responses
---------------------

The median (range) coma recovery time and time to death were 24 (1--188) h (N = 46) and 44 (2--641) h (N = 76) respectively (Table [9](#T9){ref-type="table"}). Artemisinin derivative-based therapy was given to 378/958 (39%) of patients starting in 1993, and artesunate or artemether was given to 317/759 (42%) of those administered a parenteral anti-malarial. A significantly higher proportion of patients had severe disease (as defined using adapted AQ criteria) in the artemisinin derivative group (46%) than the non-artemisinin group (40%) (P \< 0.001). However, the mortality in those given parenteral artesunate or artemether (16/317, 5%) was lower than those given parenteral quinine (59/442, 13%) (P \< 0.001). No patient without severe disease who received oral anti-malarial treatment died. The post-admission development of complications such as oliguria, seizures or pulmonary oedema and the use of ventilation, lumbar puncture, transfusion and inotropes, were all associated with death (Table [10](#T10){ref-type="table"}). Mortality decreased with time, from 9% in 1986--1992 to 7% in 1993--1998 and 6% in 1999--2002 (OR = 0.943 (0.896-0.994), P = 0.030). There was increasing use of artemisinin derivatives over the same periods (0%, 72% and 93% of patients, respectively) and the corresponding percentages of parenteral treatments that were with intravenous/intramuscular artemisinin derivative were 0%, 67% and 93%, respectively. After adjusting for treatment type and study site, there was no trend in mortality over time (OR = 0.961 (0.847-1.091), P = 0.538).

###### 

**Anti-malarial dr**u**g treatment and outcome**

  **Variable**                                                                                                             **All**       **Alive**   **Died**                         
  ------------------------------------------------------------------------------------------------------------------------ ------------- ----------- ----------- ------ ------------- ------
  Non-artemisinin/artemisinin derivative therapy                                                                           580/378       60.5        521/362     59.0   59/16         78.7
  Parenteral quinine/artemisinin derivative. Patients given both parenteral quinine and artemisinin derivatives excluded   430/276       60.9        371/261     58.7   59/15         79.7
  Oral quinine/artemisinin derivative and no parenteral anti-malarial                                                      93/60         60.8        93/60       60.8   0/0           \-
  Number given/not given antibiotic ^a^                                                                                    124/818       13.2        94/778      10.8   30/40         42.9
  No. given/not given inotrope                                                                                             65/872        6.9         13/856      1.5    52/16         76.5
  No. given/not given anti-epileptic drug                                                                                  97/843        10.3        59/812      6.8    38/31         55.1
  No. given/not given nasogastric tube                                                                                     65/859        7.0         36/828      4.2    29/31         48.3
  No. given/not given urinary catheter                                                                                     207/728       22.1        142/725     16.4   65/3          95.6
  No. given/not given blood transfusion                                                                                    160/828       16.2        132/779     14.5   28/49         36.4
  No. given/not given dialysis                                                                                             31/898        3.3         7/854       0.8    24/44         77.4
  No. given/not given ventilation                                                                                          85/845        9.1         25/839      2.9    60/6          90.9
  No. given/not given central venous access line                                                                           99/840        10.5        45/825      5.2    54/15         78.3
  No. given/not given lumbar puncture                                                                                      90/849        9.6         56/813      6.4    34/36         48.6
  No. developing/not developing pulmonary oedema                                                                           14/958        1.4         7/888       0.8    7/70          9.1
  No. developing/not developing oliguria                                                                                   94/843        10.0        43/826      5.0    51/17         75.0
  No. developing/not developing seizures                                                                                   39/909        4.1         20/852      2.3    19/57         25.0
  No. of nights in hospital^b^                                                                                             4 (1--34)     \-          4 (1--34)   \-     2 (1--27)     \-
  Coma Recovery Time/h^b^                                                                                                  24 (1--188)   \-          \-          \-     \-            \-
  Time to death/h^b^                                                                                                       \-            \-          \-          \-     44 (2--641)   \-

^a^ excluding doxycycline and tetracycline given for malaria. ^b^ Median (range). All comparisons between alive and dead were statistically significant (P \< 0.001, adjusted for study site).

###### 

Summary of multiple logistic regression models for outcome for Bedside and WHO models

  **Covariate**                      **OR**              **95% CI**   **P value**   **AUROCC 95% CI**   
  ---------------------------------- ------------------- ------------ ------------- ------------------- ------------------
  **Bedside**                                                                                           0.93 (0.90-0.96)
  Anaemia                            2.510               1.173        5.373         0.018                
  Jaundice                           3.235               1.534        6.823         0.002                
  Temperature ^0^C                   0.673               0.490        0.926         0.015                
  Pulse/min                          1.031               1.007        1.056         0.010                
  Respiratory rate/min               1.061               1.010        1.115         0.018                
  GCS                                0.717               0.654        0.785         \<0.001              
  Treatment with ACT                 0.387               0.134        1.118         0.080                
  **Bedside + Simple Lab**           0.96 (0.93 -0.98)                                                  
  Temperature ^0^C                   0.579               0.405        0.829         0.003                
  Respiratory rate/min               1.081               1.027        1.139         0.003                
  Log~10~ parasitaemia               8.606               3.525        21.011        \<0.001              
  GCS                                0.663               0.589        0.745         \<0.001              
  \% Trophozoites and schizonts      1.029               1.014        1.045         \<0.001              
  Treatment with ACT                 0.253               0.078        0.825         0.023                
  **WHO (1990)**                     0.95 (0.90-1.00)                                                   
  GCS                                0.673               0.590        0.767         \<0.001              
  Serum creatinine μmol/L            1.005               1.001        1.009         0.007                
  Serum bicarbonate mmol/L           0.844               0.763        0.934         0.001                
  Serum total bilirubin μmol/L       1.006               1.001        1.010         0.011                
  Log~10~ parasitaemia               1.902               1.060        3.410         0.031                
  Treatment with ACT                 0.838               0.224        3.142         0.794                
  **WHO (2000) and Adapted AQ**^a^   0.97 (0.96-0.99)                                                   
  GCS                                0.673               0.582        0.778         \<0.001              
  Serum bicarbonate mmol/L           0.856               0.747        0.980         0.024                
  Serum lactate mmol/L               1.197               1.052        1.362         0.006                
  Log~10~ parasitaemia               2.460               1.168        5.182         0.018                
  Serum creatinine μmol/L            1.006               1.002        1.010         0.003                
  Treatment with ACT                 1.000               0.220        4.555         1.000                

All estimates are adjusted for treatment with ACT and study site. ^a^ the same variables were identified from the WHO (2000) and Adapted AQ models.

Relationships between clinical syndromes
----------------------------------------

Of 111 patients with cerebral malaria (GCS \< 11), 97 had evaluable data. Of these, 68 (70%) had plasma lactate \>4 mmol/L and/or serum bicarbonate \<15 mmol/L and/ or serum creatinine \>264 μmol/L, and 36 (53%) of these died compared with three (10%) among 29 cerebral malaria patients without these abnormalities (P = 0.001). Among cerebral malaria patients, mortality did not significantly differ between those with and without jaundice (total serum bilirubin \>50 μmol/L): 42% (23/55) *versus* 34% (15/44) (P = 0.547). Mortality was higher in patients with renal impairment; 82% (18/22) in those with a serum creatinine \>264 μmol/L compared with 28% (23/83) in those with lower levels (P \< 0.001).

Multiple logistic regression analysis of variables associated with death
------------------------------------------------------------------------

All final models were adjusted for treatment with ACT and study site. No interactions between covariates and treatment were significant in any of the models and study site was not significant (P \> 0.05). Tables [10](#T10){ref-type="table"} and [11](#T11){ref-type="table"} list variables included in each of the eight final models, all having a maximum of eight variables, consistent with recommendations \[[@B31]\].

###### 

Summary of multiple logistic regression models for outcome for Adapted AQ + pigmented stages, BCAM and RCAM models

  **Covariate**                       **OR**   **95% CI**   **P value**   **AUROCC 95% CI**   
  ----------------------------------- -------- ------------ ------------- ------------------- ------------------
  **Adapted AQ + pigmented stages**                                                           0.97 (0.96-0.99)
  GCS                                 0.728    0.641        0.828         \<0.001              
  Plasma lactate mmol/L               1.341    1.190        1.510         \<0.001              
  Serum creatinine μmol/L             1.006    1.003        1.009         \<0.001              
  \% Trophozoites & schizonts         1.026    1.009        1.043         0.003                
  Log~10~ parasitaemia                4.064    1.506        10.969        0.006                
  Treatment with ACT                  0.438    0.103        1.869         0.265                
  **BCAM**                                                                                    0.92 (0.87-0.97)
  GCS/15                              0.718    0.652        0.791         \<0.001              
  Serum bicarbonate mmol/L            0.780    0.717        0.849         \<0.001              
  Treatment with ACT                  0.718    0.230        2.237         0.568                
  **RCAM**                                                                                    0.88 (0.84-0.93)
  GCS/15                              0.680    0.627        0.736         \<0.001              
  Respiratory rate/min                1.097    1.055        1.141         \<0.001              
  Treatment with ACT                  0.329    0.126        0.857         0.023                

All estimates are adjusted for treatment with ACT and study site.

Considering the WHO- and AQ-based models, the WHO 1990, WHO 2000, Adapted AQ and Adapted AQ + Pigmented stages, variable sets gave the best predictive power and the areas under the ROC curves (AUROCCs) were not significantly different (Tables [10](#T10){ref-type="table"} and [11](#T11){ref-type="table"}, Additional files [2](#S2){ref-type="supplementary-material"}, [3](#S3){ref-type="supplementary-material"}, and [4](#S4){ref-type="supplementary-material"}). Models derived from bedside or bedside + simple laboratory covariates had significantly smaller AUROCCs, when compared to the Adapted AQ model using the common data set (P = 0.008 and 0.016, respectively). Several variables appeared in all four 'best' models and had similar effects across models, such as GCS (OR 0.67-0.73 for increase by one point), serum bicarbonate (OR 0.84-0.86 for increase of 1 mmol/L), plasma lactate (OR 1.20-1.34 for increase of 1 mmol/L), parasitaemia (OR 1.90-4.06 for ten-fold increase) and serum creatinine (OR 1.005-1.006 for increase of 1 μmol/L).

The BCAM and RCAM scores could be calculated for 662 and 873 patients, respectively, and mortality rose with increasing score for both (Table [12](#T12){ref-type="table"}). Of 498 patients with a low BCAM (\<2) score, three (0.6%) died (PPV (95%CI) for survival 99.4 (98.2--99.8)%), and of the 675 patients with low RCAM (\<2) score, 11 (1.6%) died (PPV for survival 98.4 (97.1-99.1)%). The BCAM score AUROCC as a predictor for mortality was 0.907 (0.861-0.953) and that for the RCAM score 0.86 (0.81-0.91)(P = 0.050). A score \<2 was an optimal cut-off value in this data set for both BCAM and RCAM, with sensitivity and specificity of 93.8% and 80.6% for BCAM and 81% and 81% for RCAM.

###### 

Mortality among patients by BCAM and RCAM scores

  **Score, Outcome**   **0**         **1**          **2**           **3**          **4**          **Total**
  -------------------- ------------- -------------- --------------- -------------- -------------- --------------
  **BCAM**                                                                                         
  Died/total (%)       1/124 (0.8)   2/374 (0.5)    12/79 (15.2)    16/60 (26.7)   17/25 (68.0)   48/662 (7.3)
  **RCAM**                                                                                         
  Died/total (%)       0/97 (0)      11/578 (1.9)   12/108 (11.1)   25/74 (33.8)   11/16 (68.8)   59/873 (6.8)

For the MSA score \[[@B22]\] (Additional file [1](#S1){ref-type="supplementary-material"}) using admission variables plus the presence or absence of mechanical ventilation during admission where such ventilation was available (all sites except Sangklaburi) for 635 patients, 516 (81.3%) had an MSA score of 0. Mortality was 2/539 (0.4%) for MSA 0--2, 10/45 (22.2%) for MSA 3--4, 5/12 (41.7%) for MSA 5--6 and 24/39 (61.5%) for MSA ≥7. If ≥5 is taken as the cut off, the PPV for survival was 97.9 (96.4-98.8)%. Among patients who had MSA and BCAM scores calculated (n = 527) the AUROCC for the MSA score in predicting death was 0.97 (0.95-0.98), which was significantly better than that for the BCAM score 0.90 (0.84-0.96) (P = 0.007). The optimal cut off for the data presented here appeared to be \<3 rather than \<5 as reported \[[@B22]\]; with a cut off of \<3 the PPV was 99.6 (98.7-100.0)%, sensitivity 95.1% and specificity 90.4%.

Considering all ten models, those based on the MSA score and the Adapted AQ with pigmented parasites had the best predictive power, but AUROCCs for models based on WHO criteria were not significantly lower. Simple rules for classification of severity as a MPI (Table [13](#T13){ref-type="table"}, Figure [1](#F1){ref-type="fig"}), gave sensitivity of 100% and specificity of 82% with co-efficient of 3 rounded to the nearest integer, and sensitivity of 93% and specificity of 92% for a cut off of 4. When compared to the best performing models, based on MSA and Adaptive AQ + Pigmented stages, MPI showed equally good predictive power: AUROCC = 0.96 (0.95-0.98) for MPI rounded to the nearest integer, and 0.97 (0.96-0.99) for MPI rounded to the nearest 0.5 compared to 0.98 (0.96-0.99) for MSA and 0.97 (0.94-0.99) for AQ dataset, based on 450 patients who could be evaluated in all four models. In cross-validation, in all runs, the best sensitivity and specificity were obtained for cut offs between 3 and 4 (Figure [2](#F2){ref-type="fig"}). For a cut off of 3, the jacknife sensitivity and specificity were 97.1% and 87.1%; for a cut off of 3.5 they were 97.1% and 87.1%; and for a cut off of 4 they were 74% and 94%.

###### 

Prognostic index for severe malaria

  **N = 668 / n = 43**              **Co-efficient**          
  --------------------------------- ------------------ ------ ------
  GCS \<5                           4.318              4      4.5
  GCS 5-11                          1.543              2      1.5
  Parasitaemia \>315,000/μL         1.238              1      1
  Plasma lactate \> 5 mmol/L        2.267              2      2.5
  Serum bilirubin \> 58 μmol/L^1^   1.191              1      1
  Pigmented parasites \>20%         1.673              2      1.5
  Treatment with ACT                −1.280             −1     −1.5
  AUROCC                            0.97               0.97   0.97
  Cut off ^2^                                          3      3
  Sensitivity                                          100%   100%
  Specificity                                          82%    88%
  Cut off ^3^                                          4      3.5
  Sensitivity                                          93%    95%
  Specificity                                          92%    91%

MPI A = co-efficients rounded to the nearest integer with cut offs of 3.

MPI B = co-efficients rounded to the nearest 0.5 with cut offs of 3.

^1^ if not available; creatinine \>132 μmol/L can be used instead.

and cut off of 3 would give sensitivity and specificity of 98%.

and 82% for MPI A and 96% and 88% for MPI B.

^2^ which gives the highest specificity for 100% sensitivity.

^3^ which gives the "optimal" sensitivity and specificity.

![**Relationship between malaria prognostic index and mortality.** Malaria prognostic indices MPI A and MPI B are defined in Table [13](#T13){ref-type="table"}.](1475-2875-12-229-1){#F1}

![Sensitivity (filled circle) and specificity (empty circle) for different cut offs of malaria prognostic index in cross validation.](1475-2875-12-229-2){#F2}

Discussion
==========

The prognosis of severe falciparum malaria has improved markedly since the introduction of parenteral artesunate \[[@B21],[@B32]\]. This large series describing patients with falciparum malaria admitted to hospitals in western Thailand spanned the transition from quinine to artemisinins, and although the data were not from a randomized comparison, mortality was substantially lower in patients who received artemisinin derivatives. Despite the effect of changes in anti-malarial therapy, prognostic indices based on WHO 2000 definitions, and other simpler indices based on fewer variables, provided clinically useful predictions of outcome in Asian adults with severe malaria.

Models using variable sets based on WHO 2000 and Adapted AQ with pigmented stages gave the best prediction of mortality, and were comparable to the results based on the MSA score using a smaller sample. Very similar results were also obtained with the MPI based on the most commonly selected variables, GCS, plasma lactate, parasitaemia, serum bilirubin and percentage of pigmented parasites. This will need to be evaluated in independent series of adults with falciparum malaria in similar settings of unstable malaria transmission. This score suffers from the disadvantage, unlike the RCAM score, that determination of 4/5 variables (all except GCS) requires skilled technicians and equipment/consumables and quality assurance that are seldom available where severe malaria is common.

There are at least four limitations of this analysis: specifically, not all patients admitted to the study hospitals were recruited, recruitment criteria varied, there are missing values, and a variety of different doctors reviewed the patients with consequent variability in the nature of both clinical assessment and inpatient management. However, any such differences are likely to result in false negative, rather than false positive associations. The MSA score differs from the others scores discussed, as it is not strictly an admission predictive prognostic score, including mechanical ventilation during hospitalization. Some potential prognostic factors such as haemoglobinuria and abnormal bleeding were too infrequent to allow reliable conclusions to be drawn. Serum bilirubin and plasma lactate were not measured in the South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) and therefore the MPI could not be calculated for this dataset \[[@B21]\].

This study differs from that of Hanson \[[@B23]\], which only included patients classified as having severe malaria and was designed to determine which subset of patients could safely be managed without ICU referral. This is reflected in the relatively low mortality in the series described here, as severe malaria was not necessarily a criterion for recruitment. The broader patient population included may well explain the inclusion of parasitaemia as predictive of death in this series and not in that of Hanson \[[@B23]\]. As this series includes many patients without severe disease, the specificity of variables in predicting death may be higher than in series including patients with pre-selected severe disease. However, in busy clinical practice a tool that could define unselected patients admitted to hospital as at risk of death would be valuable.

The wide variation in mortality estimates in this dataset among those with severe malaria (10-18%) and indeed the wide range of estimates of severe disease (6--60%), depending on which definition is used, illustrates the importance of definitions in comparisons between studies, in meta-analyses, and in understanding the host and geographical variability in the presentation and outcome of severe malaria. Various terms, such as 'uncomplicated' and 'mild', are used to refer to malaria that is not severe. Severe disease is also equated with 'complicated' malaria. To avoid confusion, terminology should be standardized with 'severe' malaria referring to malaria with clinical and/or laboratory features suggesting a clinically significant risk of death (e.g. \>5%) despite anti-malarial treatment, and 'uncomplicated' as those without such prognostic features and that the terms 'complicated' and 'mild' are not used.

The present study suggests that, if laboratory tests are available, the history of the illness and the physical examination, apart from GCS and respiratory rate, are relatively unimportant in assessing prognosis in a population of malaria patients. Unlike in other series \[[@B13]\], increased age was not associated with death, except for those treated with quinine. However, as this series did not include children and a smaller percentage (7.7%) were \>50 years old, the age range was narrower.

In this series, the mortality of cerebral malaria was increased three-fold if concurrent acidosis and/or renal failure were present and these factors are crucial in predicting death. The ease of identifying patients with cerebral malaria may have made study of other complications less of a focus and these data suggest that more research on the pathophysiology and treatment of acidosis and renal dysfunction would provide information that would improve management and outcome \[[@B12],[@B14],[@B32]\]. The use of relatively inexpensive plasma lactate portable meters may assist in the triage of patients in tropical hospitals without access to biochemical analyzers, and interventions directed at acidosis and renal impairment might reduce mortality. Although capital costs for veno-venous haemofiltration are relatively high, and intensive care support is required, running costs in comparison to peritoneal dialysis are low \[[@B33]\]. In areas of the Asiatic tropics with good communications but low health expenditure, regional centres for the management of severe malaria through haemofiltration may assist in lowering mortality.
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